Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012)

Craig S Boddy, MD, Charles L Bennett, MD PhD MPP, LeAnn B Norris, PharmD, Peter Georgantopoulos, MPH, MA, Suhong Luo, MPH, Kenneth R Carson, MD

Blood (2014) 124 (21): 4456.

https://doi.org/10.1182/blood.V124.21.4456.4456

Published: 2014

Journal Articles

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

Virginia Noxon, Charles L Bennett, MD PhD MPP, Jun Wu

Blood (2014) 124 (21): 1276.

https://doi.org/10.1182/blood.V124.21.1276.1276

Published: 2014

Journal Articles

Introduction of a Quick Assay for ADAMTS13 Activity Improved a Survival of Acquired TTP Patients Who Received Platelet Transfusions

Yumi Yoshii, MD, Masanori Matsumoto, MD PhD, Kurumatani Norio, MD PhD, Ayami Isonishi, BS, Masahito Uemura, MD PhD, Yuji Hori, PhD, Masaki Hayakawa, MD, Hideo Yagi, MD PhD, Charles L Bennett, MD PhD MPP, Yoshihiro Fujimura, MD PhD

Blood (2014) 124 (21): 4209.

https://doi.org/10.1182/blood.V124.21.4209.4209

Published: 2014

Journal Articles

Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis

Alyssa Trenery, Samuel Kessler, BA, Van Slooten Eleasa, BS, Akida Lebby, Charles L. Bennett, MD, PhD, MPP, Paul Yarnold, PhD, Paul Ray, DO, MA, Dennis W. Raisch, PhD, MS, RPh, Gowtham Rao, MD, PhD, Peter Georgantopoulos, MPH, MA, LeAnne Norris, PharmD, Simone Boyle, BA, Ashlyn Byrne, Matthew Bialkowski, Oliver Sartor, MD

Blood (2013) 122 (21): 2938.

https://doi.org/10.1182/blood.V122.21.2938.2938

Published: 2013

Journal Articles

Fatal and Serious Anaphylaxis Following Peginesatide Administration

Charles L. Bennett, MD, PhD, MPP, Sony Jacob, MD, Iain C Macdougall, MD, Tom Moore, Peter Georgantopoulos, MPH, MA, Judy Nichols, Paul Yarnold, PhD, Oliver Sartor, MD, Dennis W. Raisch, PhD, MS, RPh, Ashraf Mikhail, MD, LeAnn Norris, PharmD, Samuel Kessler, BA, Jametta Magwood, BA, David Goldsmith, MB, ChB

Blood (2013) 122 (21): 5612.

https://doi.org/10.1182/blood.V122.21.5612.5612

Published: 2013

Journal Articles

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Elizabeth A Richey, BA, Veena Shankaran, MD, Steven Hirschfeld, MD, PhD, Steven M Trifilio, RPh, June McKoy, MD, MPH, Kenneth R Carson, MD, Beatrice J Edwards, MD, FACP, Thanh Ha Luu, BA, Narissa Nonzee, BS, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2402.

https://doi.org/10.1182/blood.V112.11.2402.2402

Published: 2008

Journal Articles

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Monica Boen, BA, June McKoy, MD, MPH, Dennis West, Beatrice Edwards, Jayesh Mehta, Seema Singhal, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 2403.

https://doi.org/10.1182/blood.V112.11.2403.2403

Published: 2008

Journal Articles

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Cara C Tigue, BA, Dennis P West, PhD, Dennis W Raisch, PhD, RPh, Beatrice J Edwards, MD, FACP, Simone N Boyle, BA, Athena T Samaras, BA, Paul Bennett, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4662.

https://doi.org/10.1182/blood.V112.11.4662.4662

Published: 2008

Journal Articles

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Charles L. Bennett, MD, PhD, MPP, Benjamin Kim, MD, Athena T Samaras, BA, Allen R Nissenson, MD, FACP, A. Oliver Sartor, MD, D. Mark Courtney, MD, Robert I. Liem, MD, Dennis P West, PhD, Simone N Boyle, BA, Robin L Wagner, Carolyn E Goldstein, Steven M Trifilio, RPh, David M Spiegel, MD, FACP, Stephen Y Lai, MD, PhD

Blood (2008) 112 (11): 4680.

https://doi.org/10.1182/blood.V112.11.4680.4680

Published: 2008

Journal Articles

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Athena T Samaras, BA, Sara E Barnato, MD, Benjamin Kim, MD, Stephen Y Lai, MD, PhD, A. Oliver Sartor, MD, June McKoy, MD, JD, MPH, Brian C Sauer, PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 4681.

https://doi.org/10.1182/blood.V112.11.4681.4681

Published: 2008

Journal Articles

Multiple Non-Linear Epitopes of ADAMTS13 Were Targeted by Anti- ADAMTS13 IgG in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura

Dezhi Shang, Haifeng Wu, Spero Cataland, Charles L. Bennett, MD, PhD, MPP, Hau C. Kwaan, X. Long Zheng

Blood (2008) 112 (11): 276.

https://doi.org/10.1182/blood.V112.11.276.276

Published: 2008

Journal Articles

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

Wendy Oatis, MD, JD, Veena Shankaran, MD, Faisal Saghir, MD, Charles L. Bennett, MD, PhD, MPP, Elizabeth Richey, BA, James B Bussel

Blood (2008) 112 (11): 3433.

https://doi.org/10.1182/blood.V112.11.3433.3433

Published: 2008

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

Journal Articles

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Sara E Barnato, MD, Simone N Boyle, BA, Adam Kuykendal, MD, Stephen Y Lai, MD, PhD, Robin L Wagner, Carolyn E Goldstein, Athena T Samaras, BA, Dennis P West, PhD, Jacob Tallman, Michael Henke, MD, A. Oliver Sartor, MD, Charles L. Bennett, MD, PhD, MPP

Blood (2008) 112 (11): 672.

https://doi.org/10.1182/blood.V112.11.672.672

Published: 2008

Journal Articles

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Charles L. Bennett, MD, PhD, MPP, Thanh Ha Luu, BA, Anaadriana Zakarija, MD, Hau C. Kwaan, MD, PhD, Nicholas Bandarenko, MD, Dilip K. Pandey, MBBS, MS, PhD, John F. Cursio, MS, June M. McKoy, MD, JD, MPH, Charlie Buffie, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD, Ravindra Sarode, MD, X. Long Zheng, MD, PhD, Thomas J. Raife, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Gail A. Rock, MD, PhD

Blood (2007) 110 (11): 2088.

https://doi.org/10.1182/blood.V110.11.2088.2088

Published: 2007

Journal Articles

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Elizabeth A. Richey, BA, Charles L. Bennett, MD, PhD, MPP, Hau C. Kwaan, MD, PhD, Anaadriana Zakarija, MD, MSCI, Nicholas Banderanko, MD, Dilip K. Pandey, MD, PhD, June M. McKoy, MD, JD, MPH, Paul R. Yarnold, PhD, Dennis W. Raisch, PhD, Jeffrey L. Winters, MD, Thomas J. Raife, MD, John F. Cursio, MS, Matthew J. Fisher, Thomas L. Ortel, MD, PhD, Martin S. Tallman, MD, Masanori Matsumoto, MD, PhD, Yoshihiro Fujimura, MD, PhD, Joel L. Moake, MD

Blood (2007) 110 (11): 2089.

https://doi.org/10.1182/blood.V110.11.2089.2089

Published: 2007

Journal Articles

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Sara E. Barnato, MD, Charles L. Bennett, MD PhD MPP, Kathleen Elverman, Dennis P. West, PhD, Mark Courtney, MD

Blood (2007) 110 (11): 962.

https://doi.org/10.1182/blood.V110.11.962.962

Published: 2007

Journal Articles

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Nina Undevia, MD MPH, Cara C. Tigue, BA, Dennis P. West, PhD, June M. McKoy, MD MPH JD, Beatrice J. Edwards, MD, David A. Dorr, MD MS, Dennis W. Raisch, RPh PhD, Charles L. Bennett, MD, PhD, MPP

Blood (2007) 110 (11): 3339.

https://doi.org/10.1182/blood.V110.11.3339.3339

Published: 2007

Journal Articles

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Anaadriana Zakarija, MD, Hau C. Kwaan, MD PhD, Nicholas Banderanko, MD, Dilip K. Pandey, MD PhD, John F. Cursio, MS, Ivy M. Weiss, BA, Thanh Ha Luu, BA, Jeffrey L. Winters, MD, Thomas L. Ortel, MD PhD, Thomas J. Raife, MD, Ravindra Sarode, MD, Charles L. Bennett, MD PhD MPP

Blood (2007) 110 (11): 1320.

https://doi.org/10.1182/blood.V110.11.1320.1320

Published: 2007

Journal Articles

Inadvertent Intrathecal Administration of Vincristine.

Praveena Basetty, MD, Charlie G. Buffie, BA, Jennifer Lagman, RN, Cara C. Tigue, BA, Neal Dandade, BA, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3327.

https://doi.org/10.1182/blood.V108.11.3327.3327

Published: 2006

NARROW

Rituximab-Associated Progressive Multifocal Leukoencephalopathy (PML) in HIV-Negative Patients: An Updated Report of 231 Confirmed Cases from the Southern Network on Adverse Reactions (SONAR)/Washington University Collaboration (2000-2012)

The Reduction of Erythropoietin Stimulating Agent (ESA) Use Due to the FDA Black Box Warning

Introduction of a Quick Assay for ADAMTS13 Activity Improved a Survival of Acquired TTP Patients Who Received Platelet Transfusions

Conflicts Of Interest In Pharmaceutical Sponsored Research On Erythropoietin Receptors In Cancer: An Updated Analysis

Fatal and Serious Anaphylaxis Following Peginesatide Administration

“Getting to go” for FDA Approvals for the Treatment of Hematologic Versus Solid Tumor Malignancies: A Report from the Research on Adverse Drug Events and Reports (RADAR) Project

Thalidomide (thal), Lenalidomide (len), and Dexamethasone (dex)-Associated Venous Thromboembolism (VTE) and Reported VTE Rates Pre- and Post-FDA Approval: Optimal Prophylaxis Strategies Are Still Unclear

Novel Dissemination Efforts for Hematology-Related Serious Adverse Drug Reactions (sADRs): Findings from the Research on Adverse Drug Events and Reports Project (RADAR)

Erythropoiesis Stimulating Agent (ESA) Use for Anemic Cancer and Chronic Kidney Disease (CKD) Patients in 2008: Advocacy for Conservative Use

Evaluating Mortality with Erythropoietin Stimulating Agents (ESAs) in the Oncology Setting: The Importance of Selecting Trials That Include Survival or Loco-Regional Tumor Control as a Primary Endpoint

Multiple Non-Linear Epitopes of ADAMTS13 Were Targeted by Anti- ADAMTS13 IgG in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura

A Predictive Cost-Effectiveness Analysis of the Treatment of Chronic, Refractory Immune Thrombocytopenic Purpura (ITP) with Novel Agents: An Economic Model Based on Long-Term Treatment Data with Rituximab Versus Romiplostim.

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Evaluation of Conflicts of Interest in Basic Science Studies Evaluating Erythropoietin and Erythropoietin Effects of Solid Cancer Cell Lines

Clinical and Outcomes Findings for Thrombotic Thrombocytopenic Purpura among 467 Persons with Severely Versus Not Severely Deficient ADAMTS-13 Levels.

Ticlopidine- and Clopidogrel-Associated Thrombotic Thrombocytopenic Purpura (TTP): Final Results from the Surveillance Epidemiology and Risk Factor-TTP Study Group.

Evaluating Mortality with Erythropoietic Stimulating Agents (ESAs) in the Nephrology Setting: The Distinction between Evaluating Trials That Measure Survival as a Primary or Secondary Efficacy Endpoint Versus a Safety Endpoint.

Rapid Identification of Hematology-Associated Serious Adverse Drug Reactions (sADRS) with Small Datasets: Findings from the Research on Adverse Drug Events and Reports (RADAR) Project.

Distinct Clinical Syndromes Are Defined by ADAMTS13 Activity in Idiopathic TTP: Results of the SERF-TTP Study.

Inadvertent Intrathecal Administration of Vincristine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only